GLP-1 Receptor Agonists as Candidate Geroprotectors
Current understanding
GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) are being reframed from glycemic/weight agents to candidate gerotherapeutics on the basis of RCT mortality and kidney-outcome signals that appear only partially explained by weight or glucose lowering [human-rct], plus first randomized 2025 evidence that semaglutide decelerates validated DNA-methylation aging clocks [human-rct]. Proposed mechanistic substrates span central and peripheral GLP-1R signaling into inflammation, autophagy/mTOR crosstalk, vascular biology, and gut–brain communication [mechanism-plausible]. Definitive aging-endpoint trials do not yet exist, and the biology-to-gerotherapeutic pitch outruns the current evidence base.
Evidence log
- 2026-11-10 — Nutrition Care Strategies at the Intersection of Menopause and Obesity Pharmacotherapy.: cross-connection with menopause-estrogen-decline: [expert-opinion] This clinical review connects menopausal musculoskeletal vulnerability with reduced intake during incretin-based obesity treatment, identifying muscle and bone preservation as unresolved outcomes alongside candidate geroprotective benefits rather than demonstrating that these drugs accelerate aging. (novelty: 3)
- 2026-03-31 — Reprogramming the mitochondrial-circadian energy code with incretins.: cross-connection with circadian-clock-aging: [expert-opinion] The review proposes circadian alignment as a component of incretin-mediated geroprotection, linking the candidate-drug narrative to clock biology without establishing that clock restoration mediates human benefits or that circadian entrainment adds geroprotective efficacy. (novelty: 3)
- 2026-10-29 — GLP-1 Receptor Agonists Decrease the Rate of Rupture, Cardiac Events, and Death in Patients with Abdominal Aortic Aneurysms.: cross-connection with vascular-aging: [human-observational] The matched aneurysm cohort connects candidate GLP-1 geroprotection to clinical outcomes in degenerative aortic disease, but does not establish direct vascular geroprotection or distinguish vessel-wall effects from systemic metabolic effects and residual confounding. (novelty: 3)
- 2026-07-18 — GLP1 Mimetics and Stem Cells: An Intersection of Metabolic and Regenerative Medicine.: 2026 editorial frames a GLP-1RA × stem-cell biology intersection (effects on proliferation, survival, differentiation, stemness) as a candidate regenerative axis; preclinical and conceptual, no clinical regenerative outcomes. [expert-opinion] (novelty: 3)
- 2026-09-25 — An RNA thermogenic therapy to preserve lean mass and enhance metabolic health during GLP-1 weight loss.: cross-connection with adipose-thermogenesis-beiging: ZFP423 ASO–induced adipose beiging combined with semaglutide amplifies fat loss while preserving lean mass in mice, directly addressing the lean-mass-loss liability that clouds the geroprotection narrative for GLP-1 receptor agonists. (novelty: 4)
- 2026-09-25 — The Interplay of Metabolic Dysfunction, Neuroinflammation, and Mitochondrial Dysfunction in Balance Impairment: Insights from Type 2 Diabetes Mellitus and Alzheimer’s Disease.: cross-connection with brain-glucose-metabolism-aging: GLP-1 receptor agonists are nominated as candidate interventions on the same insulin-resistance/glucotoxicity → NLRP3 → mitochondrial cycle that couples brain glucose metabolism decline to balance and motor impairment in AD and T2DM. (novelty: 3)